View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 11, 2022

Pyramid and Caris partner to boost patient matching for solid tumour trials

Caris ’customised Molecular Intelligence Trials aids in matching the right participants to the right trials.

Pyramid Biosciences and Caris Life Sciences have entered a partnership to boost potential participant identification with NTRK fusion-driven cancers for the ongoing Phase I/II PBI-200-101 clinical trial of the former’s PBI-200.

A lead oncology programme of Pyramid, PBI-200 is a CNS-penetrant TRK inhibitor.

The multicentre, open-label, international Phase I/II trial will enrol NTRK fusion-positive advanced or metastatic tumour patients, including those with primary and metastatic CNS tumours. 

It will have a dose-escalation phase and a subsequent multicohort expansion at the recommended Phase II dose of PBI-200. 

Pyramid Bio CEO Brian Lestini said: “This collaboration will further advance the promise of precision oncology, with the potential to deliver highly differentiated compounds against validated cancer targets. 

“Caris’ patient identification and matching service is invaluable for enabling the development of novel precision therapies, especially in genetically-defined populations like NTRK.”

In preclinical studies, PBI-200 demonstrated to attain increased levels of penetration into the brain, which translated to improved efficacy in intracranial xenograft models versus other TRK inhibitors. 

It was also found to possess a favourable safety profile.

Caris focuses on the development and delivery of new solutions to transform healthcare. The customised Molecular Intelligence Trials (MI Trials) of the company aid in matching the right participants to the right trials.

The matching is made based on the molecular tumour profile of the patient and the trial’s eligibility needs.

Caris provides a growing portfolio of trials through its Right-In-Time clinical trial solution, with more than 50 therapy options available.

Furthermore, over 450 research-ready trial centres are available if a patient is detected using a Caris molecular profile outside a current sponsor study site. 

This network aids in offering trials to patients who are otherwise unable to gain access to such new treatments.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU